These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 8427780

  • 1. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
    Jones M, Siracky J, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
    [Abstract] [Full Text] [Related]

  • 2. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG.
    Cancer Res; 1992 Dec 15; 52(24):6885-9. PubMed ID: 1458477
    [Abstract] [Full Text] [Related]

  • 3. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
    Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR.
    Cancer Chemother Pharmacol; 1992 Dec 15; 30(1):43-50. PubMed ID: 1586979
    [Abstract] [Full Text] [Related]

  • 4. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 5. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
    Perez RP, Perez KM, Handel LM, Hamilton TC.
    Cancer Chemother Pharmacol; 1992 Jun 01; 29(6):430-4. PubMed ID: 1568285
    [Abstract] [Full Text] [Related]

  • 6. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P, Valenti M, Kelland LR.
    Anticancer Res; 1994 Jun 01; 14(3A):1065-70. PubMed ID: 8074451
    [Abstract] [Full Text] [Related]

  • 7. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR.
    Cancer Res; 1992 Nov 15; 52(22):6188-93. PubMed ID: 1423261
    [Abstract] [Full Text] [Related]

  • 8. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Aug 15; 68(2):240-50. PubMed ID: 8347478
    [Abstract] [Full Text] [Related]

  • 9. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP, O'Dwyer PJ, Handel LM, Ozols RF, Hamilton TC.
    Int J Cancer; 1991 May 10; 48(2):265-9. PubMed ID: 2019469
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, Kim KH, Hong WS.
    Cancer Chemother Pharmacol; 1995 May 10; 35(5):441-5. PubMed ID: 7850928
    [Abstract] [Full Text] [Related]

  • 11. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
    Brooks SE, Korbut TT, Dupuis NP, Holden SA, Teicher BA.
    Cancer Chemother Pharmacol; 1995 May 10; 36(5):431-8. PubMed ID: 7634385
    [Abstract] [Full Text] [Related]

  • 12. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
    Harrap KR, Jones M, Siracky J, Pollard LA, Kelland LR.
    Ann Oncol; 1990 May 10; 1(1):65-76. PubMed ID: 2078487
    [Abstract] [Full Text] [Related]

  • 13. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR.
    Br J Cancer; 1991 Aug 10; 64(2):215-20. PubMed ID: 1892748
    [Abstract] [Full Text] [Related]

  • 14. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ, Barnard CF, Kelland LR, Harrap KR.
    Int J Cancer; 1994 Oct 01; 59(1):65-70. PubMed ID: 7927906
    [Abstract] [Full Text] [Related]

  • 15. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
    Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T.
    Biochem Pharmacol; 1996 Dec 24; 52(12):1855-65. PubMed ID: 8951344
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N.
    Anticancer Res; 1995 Dec 24; 15(2):393-8. PubMed ID: 7763011
    [Abstract] [Full Text] [Related]

  • 17. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T, Saijo N.
    Jpn J Cancer Res; 1993 Jan 24; 84(1):83-92. PubMed ID: 8383649
    [Abstract] [Full Text] [Related]

  • 18. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
    Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ.
    Cancer Chemother Pharmacol; 1993 Jan 24; 33(1):43-7. PubMed ID: 8269588
    [Abstract] [Full Text] [Related]

  • 19. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
    Misawa T, Kikkawa F, Maeda O, Obata NH, Higashide K, Suganuma N, Tomoda Y.
    Jpn J Cancer Res; 1995 Jan 24; 86(1):88-94. PubMed ID: 7737915
    [Abstract] [Full Text] [Related]

  • 20. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
    Rose WC, Basler GA.
    In Vivo; 1990 Jan 24; 4(6):391-6. PubMed ID: 2103379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.